Henan Kelun Pharmaceutical Co., Ltd.

Primary objective: This study aims to study the pharmacokinetic characteristics of a single fasting application of diclofenac diethylamine emulsion [1% (20 g: 0.2 g, calculated as C14H10Cl2NNaO2)] by healthy subjects; using diclofenac diethylamine emulsion [Voltaren®, 1% (20 g: 0.2 g, calculated as C14H10Cl2NNaO2)] by GSK Consumer Healthcare Schweiz AG and produced by GSK Consumer Healthcare SARL as the reference preparation, to compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations, and to evaluate the bioequivalence of the two preparations in humans. Secondary objective: To observe the safety of the test preparation and the reference preparation after a single application in healthy subjects.

Primary study objective: To study the pharmacokinetics of a single injection of the test preparation progesterone injection (specification: 1.112 ml: 25 mg, licensee: Henan Kelun Pharmaceutical Co., Ltd.) and the reference preparation progesterone injection (Lubion®, specification: 1.112 ml: 25 mg, licensee: IBSA Farmaceutici Italia Srl) in healthy postmenopausal female subjects under fasting conditions, and to evaluate the bioequivalence of the two preparations injected under fasting conditions. Secondary study objective: To evaluate the safety of the test preparation progesterone injection (specification: 1.112 ml: 25 mg) and the reference preparation progesterone injection (Lubion®, specification: 1.112 ml: 25 mg) in healthy postmenopausal female subjects.